Plusieurs études cliniques récentes ont indiqué son intérêt par voie sous-cutanée ou intradermique dans les douleurs neuropathiques et la névralgie faciale essentielle. Neuroscience 145:1–4Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L (2006) The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Les données les plus solides concernent la douleur neuropathique (DN) d’origine périphérique, la … La toxine botulique (TB) injectée en intramusculaire induit une atrophie et un déficit musculaires en bloquant l’exocytose de l’acétylcholine à la jonction neuromusculaire. Several recent clinical trials have indicated its beneficial impact, given subcutaneously or intradermally, on neuropathic pain and essential facial neuralgia. All rights reserved.ScienceDirect ® is a registered trademark of Elsevier B.V. J Headache Pain 17:63Attal N, Bouhassira D, Baron R, et al (2011) Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome? Pain 141:60–9Krämer HH, Angerer C, Erbguth F, et al (2003) Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. Lancet Neurol 15:555–65Han ZA, Song DH, Oh HM, Chung ME (2016) Botulinum toxin type A for neuropathic pain in patients with spinal cord injury. Pain 158:261–72Demant DT, Lund K, Vollert J, et al (2014) The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotypestratified study. L’échographie est une technique intéressante qui pourrait permettre de diminuer les douleurs lors de la phase de repérage et ceci abaisse la perception douloureuse de l’ensemble de la séance. La toxine botulique de type A est une neurotoxine puissante, largement utilisée pour le traitement des hyperactivités musculaires telles que la dystonie et la spasticité. Pflugers Arch 431:R 297–8Durham PL, Cady Rand R., Cady R (2004) Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. L’hypothèse était qu’en l’absence d’électrostimulation, le geste était moins douloureux.Étude prospective monocentrique, portant sur 107 séances d’injections des membres inférieurs. Neurology 72:1473–78Xiao L, Mackey S, Hui H, et al (2010) Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia. J Neural Transm 112:215–9Marinelli S, Vacca V, Ricordy R, et al (2012) The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes. 13:20–6Colosimo C, Tiple D, Berardelli A (2012) Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. PLoS One 7:e47977Paterson K, Lolignier S, Wood JN, et al (2014) Botulinum toxin-A treatment reduces human mechanical pain sensitivity and mechanotransduction. Cephalalgia 32:443–50Zúñiga C, Piedimonte F, Díaz S, Micheli F (2013) Acute treatment of trigeminal neuralgia with onabotulinum toxin A. Clin Neuropharmacol 36:146–50Zhang H, Lian Y, Ma Y, et al (2014) Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial.

Pain assessment was performed by the child or an accompanying party using the Visual Analog Scale (VAS) and by a health care team using the Face, Legs, Activity, Cry, Consolability (FLACC).A significant difference between the two groups was found in both self-report and by means of the behavioral observational pain scale. Attal, N. Toxine botulinique et douleurs neuropathiques. Pain 122:315–25Gazerani P, Pedersen NS, Staahl C, et al (2009) Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Ann Neurol 79:569–78Wu CJ, Lian YJ, Zheng YK, et al (2012) Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Jpn J Ophthalmol 44:106–9Purkiss J, Welch M, Doward S, Foster K (2000) Capsaïcinstimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. J Neurol 250:188–93Bach-Rojecky L, Salković-Petrisić M, Lacković Z (2010) Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. Indépendamment de cet effet myorelaxant, de nombreuses observations cliniques suggèrent par ailleurs un effet antalgique propre de la TB. Ann Neurol 64:274–83Yuan RY, Sheu JJ, Yu JM, et al (2009) Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Rev Neurol (Paris) 173:131–51Inserm U-987 et CETD, hôpital Ambroise-Paré, AP-HP, 9, avenue Charles-de-Gaulle, F-92100, Boulogne-Billancourt, FranceYou can also search for this author in Headache 44:35–42Morenilla-Palao C, Planells-Cases R, Garcia-Sanz N, Ferrer-Montiel A (2004) Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. Pain 136:380–7Attal N, Lanteri-Minet M, Laurent B, et al (2011) The specific disease burden of neuropathic pain: results of a French nationwide survey.